Table 1. Patient demographics and [18F]FSPG and [11C]acetate PET imaging results.
| Pt no. |
Age (y) |
Sex | Tumor size (cm) |
Cirrhosis | Other condition |
[18F]FSPG tumor (SUVMAX) |
[18F]FSPG liver (SUVMAX) |
[18F]FSPG tumor to liver |
[18F]FSPG detection |
[11C]acetate tumor (SUVMAX) |
[11C]acetate liver (SUVMAX) |
[11C]acetate tumor to liver |
[11C]acetate detection |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 52 | M | 2.6 | Y | HCV; MD | 2.5 | 1.0 | 2.5 | Y | 4.3 | 3.2 | 1.3 | Y |
| 2 | 68 | M | 2.8 | Y | NASH; Hem | 1.9 | 1.9 | 1.0 | N | 8.8 | 4.4 | 2.0 | Y |
| 3 | 38 | M | 4.0, 2.0 | N | HCV | 4.6, 2.4 | 1.7 | 2.7, 1.4 | Y, Y | 8.4, 6.4 | 6.1 | 1.4, 1.0 | Y, Y |
| 4 | 64 | M | 3.4 | Y | HCV | 1.9 | 1.0 | 1.9 | Y | 7.7 | 4.5 | 1.7 | Y |
| 5a | 62 | M | 4.7, 1.2 | N | HCV | 9.2, 3.8 | 0.7 | 13.1, 5.4 | Y, Y | – | – | – | – |
| 6b | 57 | F | 1.7 | Y | – | 0.7 | 0.5 | 1.4 | Y | – | – | – | – |
| 7a | 66 | M | 3.0 | N | HCV | 1.1 | 0.7 | 1.6 | Y | 5.0 | 4.5 | 1.1 | N |
| 8 | 58 | M | 3.2 | Y | HCV | 0.6 | 0.9 | 0.7 | N | – | – | – | – |
| 9 | 77 | M | 2.1, 2.1 | Y | – | 1.0, 1.1 | 1.2 | 0.8, 0.9 | N, N | – | – | – | – |
| 10b | 62 | M | 3.0, 4.0, 4.3 | Y | HCV | 6.0, 3.9, 5.4 | 1.2 | 5.0, 3.3, 4.5 | Y, Y, Y | NS, NS, 7 | 4.9 | NS, NS, 1.4 | N, N, Y |
| 11a | 72 | M | 5.1 | N | – | 5.1 | 1.8 | 2.8 | Y | 7.6 | 4.0 | 1.9 | Y |
All patients scanned with [18F]FSPG = 12/16 tumors detected for a detection rate of 75 %. For patients scanned with both [18F]FSPG and [11C]acetate, 9/10 tumors were detected by [18F]FSPG for a detection rate of 90 % and 7/10 tumors were detected by [11C]acetate for a detection rate of 70 %
Pt no. patient number, y years, SUV standardized uptake value, HCV hepatitis C, PMD porphyrin metabolism disorder, NASH non-alcoholic steatohepatitis, Hem hemochromatosis, NS not significant
a
Moderately differentiated HCC
b
Well-differentiated HCC